FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 524615 413 US

Express Mail Label Number

Date of Deposit

•	Form DTO 1300 MOD			
	Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER PC/4-32676A	
l	TRANSMITTAL LETTER TO THE UNITED STATES		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
ł	DESIGNATED/ELECTED OFFICE (DO/EO/US)		10/528323	
ŀ	CONCERNING A FILING UN			
ı	INTERNATIONAL APPLICATION NO. PCT/EP 03/10543	INTERNATIONAL FILING DATE 22 September 2003 (22.09.03)	PRIORITY DATE CLAIMED	
ŀ	TITLE OF INVENTION	22 September 2003 (22.09.03)	23 September 2002 (23.09.02)	
ļ	PROCESS FOR THE MANUFACTURE OF VALSARTAN			
APPLICANT(S) FOR DO/EO/US DENNI-DISCHERT ET AL.				
DENIA-DIGOTERY ET AL.				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
	<ol> <li>This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> </ol>			
	. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay			
	examination until the expiration of the ap	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority		
	date.	date.		
<ol> <li>A copy of the International Application as filed (35 U.S.C. 371(c)(2))</li> <li>Is transmitted herewith (required only if not transmitted by the International Bureau).</li> </ol>			al Bureau)	
b. As been transmitted by the International Bureau. (See Form PCT/IB/308)			8)	
c. is not required, as the application was filed in the United States  6. A translation of the International Application into English (35 U.S.C. 371			g Office (RO/US).	
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).				
<ul> <li>a.  are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b.  have been transmitted by the International Bureau.</li> </ul>				
c. have not been made; however, the time limit for making such amendments has NOT expired.			nts has NOT expired.	
<ul> <li>d.  \( \subseteq \) have not been made and will not be made.</li> <li>8.  \( \subseteq \) A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> </ul>			71 (c)(3)).	
	9. An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).			
	<ol> <li>A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
ltems 11. to 16. below concern document(s) or information included.				
	1. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
	12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
	13.   A FIRST preliminary amendment.			
☐ A SECOND or SUBSEQUENT preliminary amendment.				
	4. 🛛 An Application Data Sheet under 37 CFR 1.76.			
	15. A substitute specification.			
	16. A change of power of attorney and/or address letter.			
	17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.			
	18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).			
	19. A second copy of the English language to	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).		

20. 

Other items or information: unsigned declaration

DT09 Rec'd PCT/PTO 1 8 MAR 2005 S.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. PCT/EP 03/10543 PC/4-32676A The following fees are submitted: CALCULATIONS PTO USE 528323 Basic national fee. 21 \$300 22. Examination Fee If International preliminary examination report was prepared by USPTO \$ \$200 23. Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority. . . . . . . If International Search Report was prepared and provided to the Office. . . \$400 \$ 900 **TOTAL OF 21, 22 AND 23 =** Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Total Sheets Extra sheets Number of each additional 50 or fraction RATE thereof (round up to a whole number) - 100 = /50 ≈ \$ 250 \$ Surcharge of \$130 for furnishing the oath of declaration later than □ 30 \$ months from the earliest claimed priority date (37 CFR 1.492(e)). NUMBER FILED CLAIMS NUMBER EXTRA 13 - 20 = Total claims 0 X \$ 50 \$ Independent claims 5 - 3 = 2 X \$ 200 \$ 400 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$ TOTAL OF ABOVE CALCULATIONS = 1,300 Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). 1,300 SUBTOTAL = Processing fee of \$130 for furnishing the English translation later than 

30 months from the earliest claimed priority date (37 CFR 1.492(f)). TOTAL NATIONAL FEE = \$ 1,300 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property TOTAL FEES ENCLOSED = 1,300 Amount to be: refunded charged a. 🔲 A check in the amount of \$ to cover the above fees is enclosed. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,300 to cover the above fees. A b. 🛛 duplicate copy of this form is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to c. 🛛 Deposit Account No. 19-0134 in the name of Novartis.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

Send all correspondence to the address associated with Customer No. 001095, which is currently:

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 Paivi Kukkola Agent for Applicants Reg. No. 50,499 (862) 778-7875

Pan Kul